HSG4112 is an Investigational New Drug (IND) discovered by Glaceum Inc. through Quantitative Structure-Activity Relationship (QSAR) study on Glabridin and its derivatives. It is currently in Phase 1 study as a treatment for obesity. In nonclinical studies, HSG4112 showed a significant body-weight reduction effect with excellent safety profiles in Diet-Induced Obesity (DIO) mice. The test consisted of a normal control group (normal diet), a vehicle control group (high fat diet), a test group (HSG4112 100mg/kg) and a pair-fed group. HSG4112 was given orally once daily for 7 days for 6 consecutive weeks (qd×7×6). After 6 weeks, the total mean weight loss was 10.2g (-26.0%) in the test group. The contribution made by reduced food intake was 38.0% and the energy expenditure effect was 62.0%. Increase of O2 consuming and CO2 generating rates, and decrease of 5’ Adenosine Monophosphate-activated Protein Kinase (AMPK) activity in hypothalamus after oral administration of HSG4112 to DIO mice were observed. Single oral dose toxicity study of HSG4112 was performed with rat and dog. The Maximum Tolerated Dose (MTD) 2,000mg/kg was observed from both rat and dog.

In conclusion, in nonclinical studies, HSG4112 demonstrated sufficient efficacy and safety as an anti-obesity drug supporting further clinical development.
graphic
View largeDownload slide
Disclosure

S. Yoo: Employee; Self; Glaceum. K. Kim: None. I. Jo: Employee; Self; Glaceum Incoporation. K. Lim: Employee; Self; Glaceum Inc..

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.